IN2014CN00827A - - Google Patents

Info

Publication number
IN2014CN00827A
IN2014CN00827A IN827CHN2014A IN2014CN00827A IN 2014CN00827 A IN2014CN00827 A IN 2014CN00827A IN 827CHN2014 A IN827CHN2014 A IN 827CHN2014A IN 2014CN00827 A IN2014CN00827 A IN 2014CN00827A
Authority
IN
India
Prior art keywords
methods
amorphization
crystallinity
converting
typical
Prior art date
Application number
Other languages
English (en)
Inventor
John Higgins
David C Dubost
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN00827A publication Critical patent/IN2014CN00827A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN827CHN2014 2011-08-16 2012-08-10 IN2014CN00827A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524033P 2011-08-16 2011-08-16
PCT/US2012/050221 WO2013025449A1 (en) 2011-08-16 2012-08-10 Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions

Publications (1)

Publication Number Publication Date
IN2014CN00827A true IN2014CN00827A (enExample) 2015-04-03

Family

ID=47715376

Family Applications (1)

Application Number Title Priority Date Filing Date
IN827CHN2014 IN2014CN00827A (enExample) 2011-08-16 2012-08-10

Country Status (8)

Country Link
US (1) US20140206717A1 (enExample)
EP (1) EP2744481A4 (enExample)
JP (1) JP2014521745A (enExample)
CN (1) CN103732216A (enExample)
AU (1) AU2012295397A1 (enExample)
CA (1) CA2844827A1 (enExample)
IN (1) IN2014CN00827A (enExample)
WO (1) WO2013025449A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014184378A1 (en) * 2013-05-16 2014-11-20 Sandoz Ag Tablet with increased drug load of odanacatib
EP2808012A1 (en) 2013-05-29 2014-12-03 ratiopharm GmbH Method for producing dosage form comprising odanacatib
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) * 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
EP3140284A1 (en) * 2014-05-09 2017-03-15 AbbVie Inc. Crystal forms
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
KR102359641B1 (ko) * 2016-03-31 2022-02-08 가부시키가이샤 폴라 파마 비정질화제, 비정질화제를 포함하여 이루어지는 비정질의 조성물 및 그 사용
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018072113A2 (pt) * 2016-04-29 2019-02-12 Rousselot B.V. excipiente à base de proteínas para ingredientes farmacêuticos ativos
CN105943536A (zh) * 2016-05-06 2016-09-21 杭州容立医药科技有限公司 一种固体分散体的制备方法及其应用
EP3876991A4 (en) * 2018-11-07 2022-09-28 Disruptive Pharma AB NOVEL AMORPHOUS ACTIVE PHARMACEUTICALS WITH ESSENTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE
MX2021010692A (es) * 2019-03-04 2021-10-01 Japan Tobacco Inc Dispersion solida amorfa de compuesto de pirazol-amida.
CN112023124B (zh) * 2019-06-03 2022-11-29 上海微创医疗器械(集团)有限公司 结晶型涂层及其制备方法和应用
CN112300086B (zh) * 2019-08-02 2022-03-15 苏州恩华生物医药科技有限公司 氯氮平与富马酸喹硫平共无定型物及其制备方法
EP4171515A1 (en) * 2020-06-25 2023-05-03 Omya International AG Co-ground active(s) comprising product comprising surface-reacted calcium carbonate
JP2023054766A (ja) * 2021-10-04 2023-04-14 沢井製薬株式会社 アピキサバン含有粒子、それを含む医薬組成物、及びそれらの製造方法
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物
CN116831989B (zh) * 2022-03-25 2025-11-21 天津市中西医结合医院(天津市南开医院) 一种用于评价难溶性固体分散体溶出的产品
CN117017922B (zh) * 2023-07-03 2026-02-13 青岛大学 一种克拉霉素掩味固体分散体及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509038B2 (en) * 1996-05-20 2003-01-21 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
CA2450762A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
WO2005082330A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101380474B (zh) * 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
KR20110065417A (ko) * 2008-01-03 2011-06-15 욱크하르트 리미티드 파라세타몰 및 이부프로펜을 포함하는 경구 약제학적 현탁액
US20110065800A1 (en) * 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
AR072899A1 (es) * 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support

Also Published As

Publication number Publication date
US20140206717A1 (en) 2014-07-24
EP2744481A4 (en) 2015-07-01
EP2744481A1 (en) 2014-06-25
JP2014521745A (ja) 2014-08-28
CN103732216A (zh) 2014-04-16
WO2013025449A1 (en) 2013-02-21
AU2012295397A1 (en) 2014-02-20
CA2844827A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
MX367795B (es) Inhibidores de cdk.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
AU2012214029A8 (en) Rorgammat inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2013CN09704A (enExample)
MY167126A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
PH12012502255A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
MX2015003124A (es) Formas polimorficas de enzalutamida y su preparacion.
MY163979A (en) Non-nucleoside reverse transcriptase inhibitors
MX361129B (es) Composición farmacéutica que comprende un derivado de amida que inhibe el crecimiento de células con cáncer y lubricante de sal no metálica.
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
IN2014CN03857A (enExample)
PH12013501800A1 (en) Tricyclic gyrase inhibitors
PH12013501437A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
SG10201900541QA (en) Derivatives of xanthone compounds
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MY163074A (en) Formulations comprising methylthioninium chloride
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
IN2014DN00123A (enExample)
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
CA2836488C (en) Methods for treating obesity and/or metabolic syndrome
UA104102C2 (en) α-CRYSTALLINE FORM OF CARBABENZPYRIDE
IN2012CH02984A (enExample)
UA58323U (ru) Питьевая вода для спортсменов и людей, ведущих активный образ жизни